Open-Label, Randomized, 4-Way Crossover Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2016
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 14 Jul 2014 The dosage of the ibrutinib was increased from 560 to 840 mg/dose in an additional cohort of 8 subjects to document the safety and PK.
- 01 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Apr 2013 New trial record